{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:48:07Z","timestamp":1787237287226,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,5,16]],"date-time":"2014-05-16T00:00:00Z","timestamp":1400198400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s10096-014-2124-9","type":"journal-article","created":{"date-parts":[[2014,7,26]],"date-time":"2014-07-26T11:23:33Z","timestamp":1406373813000},"page":"1675-1685","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review"],"prefix":"10.1007","volume":"33","author":[{"given":"P.","family":"Poulikakos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. S.","family":"Tansarli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Falagas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,16]]},"reference":[{"key":"2124_CR1","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1017\/S0950268807009478","volume":"136","author":"ME Falagas","year":"2008","unstructured":"Falagas ME, Karveli EA, Siempos II, Vardakas KZ (2008) Acinetobacter infections: a growing threat for critically ill patients. Epidemiol Infect 136:1009\u20131019","journal-title":"Epidemiol Infect"},{"key":"2124_CR2","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1086\/432803","volume":"41","author":"R Gaynes","year":"2005","unstructured":"Gaynes R, Edwards JR; National Nosocomial Infections Surveillance System (2005) Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 41:848\u2013854","journal-title":"Clin Infect Dis"},{"key":"2124_CR3","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1473-3099(08)70279-2","volume":"8","author":"DE Karageorgopoulos","year":"2008","unstructured":"Karageorgopoulos DE, Falagas ME (2008) Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 8:751\u2013762","journal-title":"Lancet Infect Dis"},{"key":"2124_CR4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1469-0691.2005.01351.x","volume":"12","author":"AC Gales","year":"2006","unstructured":"Gales AC, Jones RN, Sader HS (2006) Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001\u20132004). Clin Microbiol Infect 12:315\u2013321","journal-title":"Clin Microbiol Infect"},{"key":"2124_CR5","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1469-0691.2004.00942.x","volume":"10","author":"M Looveren Van","year":"2004","unstructured":"Van Looveren M, Goossens H; ARPAC Steering Group (2004) Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 10:684\u2013704","journal-title":"Clin Microbiol Infect"},{"key":"2124_CR6","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1517\/14656561003596350","volume":"11","author":"A Michalopoulos","year":"2010","unstructured":"Michalopoulos A, Falagas ME (2010) Treatment of Acinetobacter infections. Expert Opin Pharmacother 11:779\u2013788","journal-title":"Expert Opin Pharmacother"},{"key":"2124_CR7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/jac\/dkh080","volume":"53","author":"WC Ko","year":"2004","unstructured":"Ko WC, Lee HC, Chiang SR et al (2004) In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain. J Antimicrob Chemother 53:393\u2013395","journal-title":"J Antimicrob Chemother"},{"key":"2124_CR8","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/jac\/dkh485","volume":"54","author":"A Montero","year":"2004","unstructured":"Montero A, Ariza J, Corbella X et al (2004) Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 54:1085\u20131091","journal-title":"J Antimicrob Chemother"},{"key":"2124_CR9","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ijantimicag.2007.07.007","volume":"30","author":"MF Tripodi","year":"2007","unstructured":"Tripodi MF, Durante-Mangoni E, Fortunato R, Utili R, Zarrilli R (2007) Comparative activities of colistin, rifampicin, imipenem and sulbactam\/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int J Antimicrob Agents 30:537\u2013540","journal-title":"Int J Antimicrob Agents"},{"key":"2124_CR10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1128\/AAC.48.3.753-757.2004","volume":"48","author":"J Yoon","year":"2004","unstructured":"Yoon J, Urban C, Terzian C, Mariano N, Rahal JJ (2004) In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 48:753\u2013757","journal-title":"Antimicrob Agents Chemother"},{"key":"2124_CR11","first-page":"890","volume":"42","author":"W Santimaleeworagun","year":"2011","unstructured":"Santimaleeworagun W, Wongpoowarak P, Chayakul P, Pattharachayakul S, Tansakul P, Garey KW (2011) In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. Southeast Asian J Trop Med Public Health 42:890\u2013900","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"2124_CR12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB et al (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268\u2013281","journal-title":"Clin Microbiol Infect"},{"key":"2124_CR13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1046\/j.1469-0691.2002.00415.x","volume":"8","author":"AS Levin","year":"2002","unstructured":"Levin AS (2002) Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem. Clin Microbiol Infect 8:144\u2013153","journal-title":"Clin Microbiol Infect"},{"key":"2124_CR14","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/jac\/42.6.793","volume":"42","author":"X Corbella","year":"1998","unstructured":"Corbella X, Ariza J, Ardanuy C et al (1998) Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother 42:793\u2013802","journal-title":"J Antimicrob Chemother"},{"key":"2124_CR15","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1093\/jac\/dkn128","volume":"61","author":"MS Oliveira","year":"2008","unstructured":"Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS (2008) Ampicillin\/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 61:1369\u20131375","journal-title":"J Antimicrob Chemother"},{"key":"2124_CR16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.diagmicrobio.2007.04.024","volume":"59","author":"YC Tseng","year":"2007","unstructured":"Tseng YC, Wang JT, Wu FL, Chen YC, Chie WC, Chang SC (2007) Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 59:181\u2013190","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2124_CR17","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.medcli.2011.06.024","volume":"138","author":"A Hern\u00e1ndez-Torres","year":"2012","unstructured":"Hern\u00e1ndez-Torres A, Garc\u00eda-V\u00e1zquez E, G\u00f3mez J, Canteras M, Ruiz J, Yag\u00fce G (2012) Multidrug and carbapenem-resistant Acinetobacter baumannii infections: factors associated with mortality. Med Clin (Barc) 138:650\u2013655","journal-title":"Med Clin (Barc)"},{"key":"2124_CR18","doi-asserted-by":"crossref","first-page":"e52349","DOI":"10.1371\/journal.pone.0052349","volume":"7","author":"RK Shields","year":"2012","unstructured":"Shields RK, Clancy CJ, Gillis LM et al (2012) Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One 7:e52349","journal-title":"PLoS One"},{"key":"2124_CR19","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1469-0691.2006.01601.x","volume":"13","author":"LC Kuo","year":"2007","unstructured":"Kuo LC, Lai CC, Liao CH et al (2007) Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin Microbiol Infect 13:196\u2013198","journal-title":"Clin Microbiol Infect"},{"key":"2124_CR20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3346\/jkms.2011.26.3.325","volume":"26","author":"SK Lim","year":"2011","unstructured":"Lim SK, Lee SO, Choi SH et al (2011) The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections. J Korean Med Sci 26:325\u2013331","journal-title":"J Korean Med Sci"},{"key":"2124_CR21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cid\/cit253","volume":"57","author":"E Durante-Mangoni","year":"2013","unstructured":"Durante-Mangoni E, Signoriello G, Andini R et al (2013) Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 57:349\u2013358","journal-title":"Clin Infect Dis"},{"key":"2124_CR22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1179\/joc.2011.23.6.345","volume":"23","author":"MS Tasbakan","year":"2011","unstructured":"Tasbakan MS, Pullukcu H, Sipahi OR, Tasbakan MI, Aydemir S, Bacakoglu F (2011) Is tigecyclin a good choice in the treatment of multidrug-resistant Acinetobacter baumannii pneumonia? J Chemother 23:345\u2013349","journal-title":"J Chemother"},{"key":"2124_CR23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jinf.2011.08.001","volume":"63","author":"JJ Ye","year":"2011","unstructured":"Ye JJ, Lin HS, Kuo AJ et al (2011) The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii. J Infect 63:351\u2013361","journal-title":"J Infect"},{"key":"2124_CR24","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jinf.2008.04.002","volume":"56","author":"AP Betrosian","year":"2008","unstructured":"Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE (2008) Efficacy and safety of high-dose ampicillin\/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 56:432\u2013436","journal-title":"J Infect"},{"key":"2124_CR25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2334-9-26","volume":"9","author":"R Gounden","year":"2009","unstructured":"Gounden R, Bamford C, van Zyl-Smit R, Cohen K, Maartens G (2009) Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections. BMC Infect Dis 9:26","journal-title":"BMC Infect Dis"},{"key":"2124_CR26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/00365540510026869","volume":"37","author":"CM Lee","year":"2005","unstructured":"Lee CM, Lim HK, Liu CP, Tseng HK (2005) Treatment of pan-drug resistant Acinetobacter baumannii. Scand J Infect Dis 37:195\u2013199","journal-title":"Scand J Infect Dis"},{"key":"2124_CR27","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/cc5911","volume":"11","author":"ME Falagas","year":"2007","unstructured":"Falagas ME, Rafailidis PI (2007) Attributable mortality of Acinetobacter baumannii: no longer a controversial issue. Crit Care 11:134","journal-title":"Crit Care"},{"key":"2124_CR28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/00365540600951184","volume":"39","author":"AP Betrosian","year":"2007","unstructured":"Betrosian AP, Frantzeskaki F, Xanthaki A, Georgiadis G (2007) High-dose ampicillin\u2013sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii. Scand J Infect Dis 39:38\u201343","journal-title":"Scand J Infect Dis"},{"key":"2124_CR29","doi-asserted-by":"crossref","first-page":"569","DOI":"10.6061\/clinics\/2013(04)21","volume":"68","author":"MS Oliveira","year":"2013","unstructured":"Oliveira MS, Costa SF, Pedri Ed, van der Heijden I, Levin AS (2013) The minimal inhibitory concentration for sulbactam was not associated with the outcome of infections caused by carbapenem-resistant Acinetobacter sp. treated with ampicillin\/sulbactam. Clinics (Sao Paulo) 68:569\u2013573","journal-title":"Clinics (Sao Paulo)"},{"key":"2124_CR30","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/jac\/47.4.479","volume":"47","author":"MJ Rodr\u00edguez-Hern\u00e1ndez","year":"2001","unstructured":"Rodr\u00edguez-Hern\u00e1ndez MJ, Cuberos L, Pichardo C et al (2001) Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains. J Antimicrob Chemother 47:479\u2013482","journal-title":"J Antimicrob Chemother"},{"key":"2124_CR31","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1086\/340055","volume":"34","author":"GC Wood","year":"2002","unstructured":"Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA (2002) Comparison of ampicillin\u2013sulbactam and imipenem\u2013cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis 34:1425\u20131430","journal-title":"Clin Infect Dis"},{"key":"2124_CR32","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","volume":"171","author":"American Thoracic Society","year":"2005","unstructured":"American Thoracic Society; Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388\u2013416","journal-title":"Am J Respir Crit Care Med"},{"key":"2124_CR33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00134-012-2769-8","volume":"39","author":"RP Dellinger","year":"2013","unstructured":"Dellinger RP, Levy MM, Rhodes A et al (2013) Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165\u2013228","journal-title":"Intensive Care Med"},{"key":"2124_CR34","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1128\/AAC.01222-13","volume":"58","author":"ME Falagas","year":"2014","unstructured":"Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS (2014) Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother 58:654\u2013663","journal-title":"Antimicrob Agents Chemother"},{"key":"2124_CR35","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/jac\/dkl044","volume":"57","author":"ME Falagas","year":"2006","unstructured":"Falagas ME, Matthaiou DK, Bliziotis IA (2006) The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. J Antimicrob Chemother 57:639\u2013647","journal-title":"J Antimicrob Chemother"},{"key":"2124_CR36","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1086\/430912","volume":"41","author":"IA Bliziotis","year":"2005","unstructured":"Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME (2005) Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 41:149\u2013158","journal-title":"Clin Infect Dis"},{"key":"2124_CR37","first-page":"CD003344","volume":"1","author":"M Paul","year":"2014","unstructured":"Paul M, Lador A, Grozinsky-Glasberg S, Leibovici L (2014) Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 1:CD003344","journal-title":"Cochrane Database Syst Rev"},{"key":"2124_CR38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ijantimicag.2012.12.006","volume":"41","author":"KZ Vardakas","year":"2013","unstructured":"Vardakas KZ, Tansarli GS, Bliziotis IA, Falagas ME (2013) beta-Lactam plus aminoglycoside or fluoroquinolone combination versus beta-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis. Int J Antimicrob Agents 41:301\u2013310","journal-title":"Int J Antimicrob Agents"},{"key":"2124_CR39","unstructured":"FDA Drug Safety Communication (2010) Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections"},{"key":"2124_CR40","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.41.5.1127","volume":"41","author":"L Leibovici","year":"1997","unstructured":"Leibovici L, Paul M, Poznanski O et al (1997) Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 41:1127\u20131133","journal-title":"Antimicrob Agents Chemother"},{"key":"2124_CR41","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/jac\/dkm193","volume":"60","author":"L Vidal","year":"2007","unstructured":"Vidal L, Gafter-Gvili A, Borok S, Fraser A, Leibovici L, Paul M (2007) Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 60:247\u2013257","journal-title":"J Antimicrob Chemother"},{"key":"2124_CR42","doi-asserted-by":"crossref","unstructured":"Lim TP, Tan TY, Lee W et al (2011) In-vitro activity of polymyxin B, rifampicin, tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii in Singapore. PLoS One 6:e18485","DOI":"10.1371\/journal.pone.0018485"},{"key":"2124_CR43","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/ja.2009.117","volume":"63","author":"M Dizbay","year":"2010","unstructured":"Dizbay M, Tozlu DK, Cirak MY, Isik Y, Ozdemir K, Arman D (2010) In vitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii. J Antibiot (Tokyo) 63:51\u201353","journal-title":"J Antibiot (Tokyo)"},{"key":"2124_CR44","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1128\/AAC.01230-13","volume":"57","author":"O Zusman","year":"2013","unstructured":"Zusman O, Avni T, Leibovici L et al (2013) Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother 57:5104\u20135111","journal-title":"Antimicrob Agents Chemother"},{"key":"2124_CR45","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s001340000715","volume":"26","author":"M Capuzzo","year":"2000","unstructured":"Capuzzo M, Valpondi V, Sgarbi A et al (2000) Validation of severity scoring systems SAPS II and APACHE II in a single-center population. Intensive Care Med 26:1779\u20131785","journal-title":"Intensive Care Med"},{"key":"2124_CR46","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1001\/jama.1990.03450180053028","volume":"264","author":"JJ Escarce","year":"1990","unstructured":"Escarce JJ, Kelley MA (1990) Admission source to the medical intensive care unit predicts hospital death independent of APACHE II score. JAMA 264:2389\u20132394","journal-title":"JAMA"},{"key":"2124_CR47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1365-2044.2001.01763.x","volume":"56","author":"KH Polderman","year":"2001","unstructured":"Polderman KH, Girbes AR, Thijs LG, Strack van Schijndel RJ (2001) Accuracy and reliability of APACHE II scoring in two intensive care units Problems and pitfalls in the use of APACHE II and suggestions for improvement. Anaesthesia 56:47\u201350","journal-title":"Anaesthesia"},{"key":"2124_CR48","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1086\/599226","volume":"48","author":"ME Falagas","year":"2009","unstructured":"Falagas ME, Rafailidis PI (2009) Nephrotoxicity of colistin: new insight into an old antibiotic. Clin Infect Dis 48:1729\u20131731","journal-title":"Clin Infect Dis"},{"key":"2124_CR49","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/jac\/dkl441","volume":"59","author":"AY Peleg","year":"2007","unstructured":"Peleg AY, Potoski BA, Rea R et al (2007) Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 59:128\u2013131","journal-title":"J Antimicrob Chemother"},{"key":"2124_CR50","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1128\/AAC.01232-12","volume":"57","author":"J Ramirez","year":"2013","unstructured":"Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC (2013) Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem\u2013cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 57:1756\u20131762","journal-title":"Antimicrob Agents Chemother"},{"key":"2124_CR51","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1186\/cc4869","volume":"10","author":"ME Falagas","year":"2006","unstructured":"Falagas ME, Bliziotis IA, Siempos II (2006) Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case\u2013control studies. Crit Care 10:R48","journal-title":"Crit Care"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-014-2124-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-014-2124-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-014-2124-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T02:30:37Z","timestamp":1565663437000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-014-2124-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,16]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["2124"],"URL":"https:\/\/doi.org\/10.1007\/s10096-014-2124-9","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,16]]}}}